At the conclusion of this live conference, learners should be better able to:
- Outline the recommended screening tests for colorectal cancer.
- Analyze barriers to colorectal cancer screening.
- Discuss evidence comparing Peroral endoscopic myotomy (POEM) with laparoscopic heller myotomy (LHM) for achalasia.
- Explain treatment strategies for patients with esophageal motility disorders (EMD).
- Integrate endoscopic approaches in the management of EMD
- Describe the pathogenesis, diagnosis and treatment of eosinophilic esophagitis.
- Describe the types of varices commonly encountered in patients with cirrhosis.
- Develop an evidence-based treatment approach for varices that incorporates current recommendations and treatment strategies for appropriately selected patients.
- Delineate a noninvasive diagnostic approach for gastroesophageal reflux disease (GERD).
- Delineate the characteristic symptoms of gastroparesis to facilitate diagnosis.
- Summarize strategies to manage gastroparesis.
- Outline advances in recommendations for diagnosis and treatment of Crohn’s and ulcerative colitis in the 2018 and 2019 ACG guidelines.
- Review the most current perspectives and clinical guidelines for the management of inflammatory bowel disease (IBD).
- Delineate the role of biosimilar therapies in the management of IBD.
- Differentiate between common gastrointestinal disorders: irritable bowel syndrome (IBS), IBD, peptic ulcer disease.
- Analyze new and emerging management strategies for IBS.
- Outline the emerging paradigm for diagnosis and management of acute pancreatitis.
- Identify appropriate candidates with acute pancreatitis for minimally invasive approaches to treatment.
- Formulate a diagnostic evaluation strategy for patients suspected of having alcoholic hepatitis (AH)/advanced liver disease.
- Summarize medical treatments and lifestyle modifications to manage AH.
- Recognize symptoms and histologic features that support a diagnosis of autoimmune hepatitis.
- Develop strategies to identify patients at risk for or with cardiac manifestations of liver disease.
- State factors that may be used to predict which patients with compensated cirrhosis may transition to decompensated cirrhosis.
- Assess optimal management strategies for patients with decompensated cirrhosis and its consequences, including hepatic encephalopathy and hepatorenal syndrome.
- Develop evidence-based prevention and management strategy for gut dysbiosis in liver disease.
- Outline the vaccination and screening recommendations for hepatitis B virus (HBV).
- Discuss diagnostic and monitoring recommendations for HBV
- List patient and clinician barriers to optimal treatments for HBV.
- Summarize the treatment recommendations for their hepatitis C virus (HCV).
- Identify difficult-to-treat populations and discuss their HCV treatment options.
- Explain factors that increase risk for hepatocellular carcinoma (HCC) in order to optimize early recognition and diagnosis.
- Summarize challenges in the diagnosis and management of HCC.
- List the expanded donor organ criteria and novel technologies for improved organ preservation.
- Formulate treatment strategies for nonalcoholic steatohepatitis.
- Identify current and emerging treatments for primary biliary cholangitis (PBC) and PBC-associated symptoms.
In support of improving patient care, this activity has been planned and implemented by Rutgers Biomedical and Health Sciences and Global Academy for Medical Education. Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 14.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This knowledge-based activity qualifies for 14.25 contact hours of continuing pharmacy education credit. Pharmacists should claim only those contact hours actually spent participating in the activity.
This activity is awarded 14.25 contact hours. (60 minute CH) Nurses should only claim those contact hours actually spent participating in the activity.
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 14.25 Category 1 credits for completing this activity.
ABIM MOC POINTS
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 14.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
This Live activity, 7th Annual Digestive Diseases: New Advances, with a beginning date of 03/27/2020, has been reviewed and is acceptable for up to 14.25 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.